Development of a dual drug-loaded hydrogel delivery system for enhanced cancer therapy: in situ formation, degradation and synergistic antitumor efficiency

A smart γ-cyclodextrin-gated mesoporous silica delivery system with dual drug loading was constructed via dual dynamic covalent bonds in combination drug therapy.

Download Full-text

Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy

Pharmaceutics ◽

10.3390/pharmaceutics13010071 ◽

2021 ◽

Vol 13 (1) ◽

pp. 71

Author(s):

Thashini Moodley ◽

Moganavelli Singh

Keyword(s):

Cancer Therapy ◽

Mesoporous Silica ◽

Silica Nanoparticles ◽

Mesoporous Silica Nanoparticles ◽

Therapeutic Agents ◽

Metal Species ◽

Stimuli Responsive ◽

Combination Drug ◽

Incidence And Mortality

With increasing incidence and mortality rates, cancer remains one of the most devastating global non-communicable diseases. Restricted dosages and decreased bioavailability, often results in lower therapeutic outcomes, triggering the development of resistance to conventionally used drug/gene therapeutics. The development of novel therapeutic strategies using multimodal nanotechnology to enhance specificity, increase bioavailability and biostability of therapeutics with favorable outcomes is critical. Gated vectors that respond to endogenous or exogenous stimuli, and promote targeted tumor delivery without prematurely cargo loss are ideal. Mesoporous silica nanoparticles (MSNs) are effective delivery systems for a variety of therapeutic agents in cancer therapy. MSNs possess a rigid framework and large surface area that can incorporate supramolecular constructs and varying metal species that allow for stimuli-responsive controlled release functions. Its high interior loading capacity can incorporate combination drug/gene therapeutic agents, conferring increased bioavailability and biostability of the therapeutic cargo. Significant advances in the engineering of MSNs structural and physiochemical characteristics have since seen the development of nanodevices with promising in vivo potential. In this review, current trends of multimodal MSNs being developed and their use in stimuli-responsive passive and active targeting in cancer therapy will be discussed, focusing on light, redox, pH, and temperature stimuli.

Download Full-text

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Open Pharmaceutical Sciences Journal ◽

10.2174/1874844901704010001 ◽

2017 ◽

Vol 4 (1) ◽

pp. 1-10 ◽

Cited By ~ 2

Author(s):

Dazhong Chen ◽

Fangyuan Xie ◽

Duxin Sun ◽

Chuan Yin ◽

Jie Gao ◽

...

Keyword(s):

Drug Therapy ◽

Polymeric Micelles ◽

Drug Loading ◽

Drug Uptake ◽

Hybrid Nanoparticles ◽

Multiple Drug ◽

Combined Chemotherapy ◽

Combination Drug Therapy ◽

Combination Drug

Background:Combined chemotherapy has gradually become one of the conventional methods of cancer treatment due to the limitation of monotherapy. However, combined chemotherapy has several drawbacks that may lead to treatment failure because drug synergy cannot be guaranteed, achievement of the optimal synergistic drug ratio is difficult, and drug uptake into the tumor is inconsistent. Nanomedicine can be a safe and effective form of drug delivery, which may address the problems associated with combination chemotherapy.Objective:This review summarizes the recent research in this area, including the use of nanoparticles, liposomes, lipid-polymer hybrid nanoparticles, and polymeric micelles, and provides new approach for combined chemotherapy.Methods:By collecting and referring to the related literature in recent years.Results:Compared with conventional drugs, nanomedicine has the following advantages: it increases bioavailability of poorly soluble drugs, prolongs drug circulation timein vivo, and permits multiple drug loading, all of which could improve drug efficacy and reduce toxicity. Furthermore, nanomedicine can maintain the synergistic ratio of the drugs; deliver the drugs to the tumor at the same time, such that two or more drugs of tumor treatment achieve synchronization in time and space; and alter the pharmacokinetics and distribution profilein vivosuch that these are dependent on nanocarrier properties (rather than being dependent on the drugs themselves).Conclusion:Therefore, nanomedicine-mediated combination drug therapy is promising in the treatment of tumors.

Download Full-text